Modelling the Interplay of Two Glycemic Biomarkers for Patient-Specific Monitoring of Diabetes.
Wednesday November 15, 2017

Odelaisy León Triana, Universidad de la Habana, Cuba

Conferencia 15 de noviembre

12:45h. E.T.S.I.Industriales, Aula 00B


Diabetes mellitus is a growing global health burden affecting about 400 million people worldwide. A person’s glycated hemoglobin reflects the average concentration of glucose in the blood over the past 2 to 3 months and is the gold standard measure for estimating the risk for diabetes-related complications in patients with disease. Remarkably there exists a transient (reversible) form known as the glycated hemoglobin labile fraction, which also provides information about the average concentration of glucose in the blood plasma at a significantly shorter time scale.  We put forward a biomathematical model to quantify the kinetics of two patient-specific glycemic biomarkers to track the emergence and evolution of diabetes mellitus: glycated hemoglobin and its labile fraction. The method incorporates erythrocyte age distribution and makes use of a large cohort of clinical data from blood sample analysis.